Morphosys Development Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals ACCESSWIRE 17 Jun 2021, 08:31 GMT+10 PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ('MorphoSys') today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ('Constellation') for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of taxes. The tender offer is being made pursuant to the previously announced merger agreement, date...

MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals MorphoSys AG (FSE: MOR; NASDAQ: MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of taxes. The tender offer is being made pursuant to the previously announced merger agreement, dated June 2, 2021 between MorphoSys and Constellation....

Constellation Pharmaceuticals DGAP-News: MorphoSys AG / Schlagwort(e): Fusionen & Übernahmen MorphoSys startet Barangebot für alle ausstehenden Aktien von Constellation Pharmaceuticals 16.06.2021 / 23:43 Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. ------------------------------------------------------------ Medienmitteilung Morpho...

Accelerates Growth Strategy by Adding Two Mid- to Late-Stage Product Candidates: Pelabresib (CPI-0610) and CPI-0209 Bolsters Position in Hematology-Oncology and Expands into Solid Tumors Best-in-Class

MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. (NASDAQ: CNST) ("Constellation") whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the Management Board ( Vorstand) and the Supervi...